Pharmacology News and Research

Latest Pharmacology News and Research

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Study presents new technique that makes drug testing possible through exhaled air

A new study from the Swedish medical university Karolinska Institutet presents a new technique that makes drug testing possible through exhaled air for the first time. By examining people who had received emergency care for an amphetamine overdose, the researchers found that in all cases there were traces of amphetamine and metamphetamine in the exhaled breath.

19 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

Tiens Biotech first-quarter revenues decrease to $11.4 million

Tiens Biotech Group (USA), Inc.,, today announced financial results for the first quarter ended March 31, 2010.

17 May 2010

UNC-developed technique has broad applications in cancer, biomedical research

A precise understanding of cellular growth and movement is the key to developing new treatments for cancer and other disorders caused by dysfunctional cell behavior. Recent breakthroughs in genetic medicine have uncovered how genes control whether cellular proteins are turned 'on' or 'off' at the molecular level, but much remains to be understood about how protein signaling influences cell behavior.

17 May 2010

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

From Parexel 13 May 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.

13 May 2010

NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents

NiKem Research is pleased to announce that it has received on March 29th 2010, from the Italian Ministry of Health (Decree N. 69/2010-B), the authorization to perform acute and sub-chronic toxicology studies (upto 28 days) in all rodent species for preliminary safety evaluation of novel chemical entities (NCEs). Toxicokinetic (TK) studies are also allowed to correlate plasma and/or organ exposure of NCEs (and metabolites) to tolerated doses in toxicology studies.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

Overtime workers at 60% higher risk of heart-related problems

Working overtime is bad for the heart according to results from a long-running study following more than 10,000 civil servants in London (UK): the Whitehall II study.

11 May 2010

SNP biomarker could reduce guesswork associated with prescribing drugs

A tiny gene mutation in human liver cells could one day influence how high or low a dose patients need of about half of the clinically used drugs on the market, new research suggests.

11 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

Fragile X syndrome iPS cells and embryonic stem cells behave differently: Study

In the last three years, a new technique for reprogramming adult cells has given scientists an easier and less controversial way to harness the power of embryonic-like stem cells to study human disease from its earliest beginnings in hopes of gleaning new insights into the root causes of disease and developing new therapies.

7 May 2010

MBPs offer no clinical benefit to patients undergoing PD: Research team

Mechanical bowel preparations are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear.

7 May 2010

NHLBI grants MU $8.47 million for research on cardiovascular diseases

One of the largest medical research grants ever awarded to the University of Missouri was announced today by MU scientists and administrators. The National Institutes of Health grant will help answer important questions about such prevalent health problems as high blood pressure, diabetes and stroke. The conditions are closely associated with cardiovascular disease, which is the leading cause of death in Missouri and the nation.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

Bone marrow stem cells show promise in multiple sclerosis

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Researchers at Johns Hopkins have discovered that a compound in dark chocolate may protect the brain after a stroke by increasing cellular signals already known to shield nerve cells from damage.

6 May 2010

Pharmacology News and Research

Latest Pharmacology News and Research

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Study presents new technique that makes drug testing possible through exhaled air

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Tiens Biotech first-quarter revenues decrease to $11.4 million

UNC-developed technique has broad applications in cancer, biomedical research

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Overtime workers at 60% higher risk of heart-related problems

SNP biomarker could reduce guesswork associated with prescribing drugs

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Fragile X syndrome iPS cells and embryonic stem cells behave differently: Study

MBPs offer no clinical benefit to patients undergoing PD: Research team

NHLBI grants MU $8.47 million for research on cardiovascular diseases

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Bone marrow stem cells show promise in multiple sclerosis

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Pharmacology News and Research

Latest Pharmacology News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in